BioMarin (BMRN) FDA Panel a 'Drisaster' - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St futures muted as oil tops $100 for first time since July
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioMarin (BMRN) Buy Rating Maintained at BofA/Merrill Lynch; FDA Vote Suggests Drisapersen Efficacy Was 'Inconclusive'
November 25, 2015 7:27 AM ESTBofA/Merrill Lynch maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a price target of $165. Comments follow the FDA panel on drisapersen, with votes suggesting that efficacy was inconclusive.
The panel viewed dystrophin as a controversial biomaker, the report... More
BioMarin (BMRN) FDA Panel Deals with Two Opposing Views - Wedbush
November 25, 2015 7:08 AM ESTWedbush analyst Heather Behanna reiterated a Neutral rating and $125 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the Drisapersen AdCom meeting.
Behanna notes that from the start, the panel dealt with two opposing views of the drisapersen data package - on the one hand, BioMarin made a case for the totality of the data on the backdrop of a... More
BioMarin (BMRN) Panel Negative, But Less than FDA - Baird
November 25, 2015 6:50 AM ESTBaird analyst Brian Skorney weighed in on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following yesterday's negative AdCom. However, the analyst said the panel was not as negative as the FDA.
"We spent yesterday at FDA for the drisapersen AdCom. The panelists... More
BioMarin Pharma (BMRN) Receives Unfavorable View from FDA Panel on Kyndrisa as DMD Treatment
November 25, 2015 6:37 AM ESTBioMarin Pharma (NASDAQ: BMRN) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) met to discuss the data submitted to support the New Drug Application (NDA) for Kyndrisa (drisapersen) for the treatment of Duchenne muscular dystrophy (Duchenne) amenable to exon 51 skipping. The committee reviewed the Kyndrisa data package, which includes three randomized, placebo controlled trials with more than 300 patients and more than 500 patient years of exposure. The committee discussed the overall strengths and weaknesses of the application but was not asked... More
BioMarin Pharma (BMRN) dystrophin data don't affect trial results - Bloomberg, Citing FDA Panel
November 24, 2015 5:03 PM ESTBioMarin Pharma (NASDAQ: BMRN) dystrophin data don't affect trial results, FDA panel says, according to Bloomberg.
... MoreBioMarin Pharma's (BMRN) Drisapersen Phase 2 Issues Don't Affect Findings - FDA Panel
November 24, 2015 3:42 PM ESTBioMarin Pharma (NASDAQ: BMRN) Kyndrisa (drisapersen) phase 2 study issues don't affect findings, FDA panel says, according to Bloomberg.
... MoreUPDATE: BioMarin Pharma's (BMRN) First Drisapersen Phase 2 has Issues - FDA Panel
November 24, 2015 3:09 PM EST(Updated - November 24, 2015 3:13 PM EST)
BioMarin Pharma (NASDAQ: BMRN) first Kyndrisa (drisapersen) phase 2 study has issues, FDA panel says, according to Bloomberg.
UPDATE - The report has nine members of the panel saying drisapersen issues weaken... More
